Ticker Details
Sage Therapeutics, Inc. Sage Therapeutics Inc is a biopharmaceutical company conducting development programs and clinical trials to discover medicines for central nervous system disorders. It has development programs for refractory status epilepticus, and Parkinson's di-sease.
IPO Date:	July 18, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$544.94M
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$1.52 | 2.53%
Avg Daily Range (30 D):	$0.04 | 0.45%
Avg Daily Range (90 D):	$0.12 | 1.65%

Institutional Daily Volume
Avg Daily Volume:	.62M
Avg Daily Volume (30 D):	2.08M
Avg Daily Volume (90 D):	1.67M

Trade Size
Avg Trade Size (Sh.):	80
Avg Trade Size (Sh.) (30 D):	259
Avg Trade Size (Sh.) (90 D):	159

Institutional Trades
Total Institutional Trades:	5,349
Avg Institutional Trade:	$2.68M
Avg Institutional Trade (30 D):	$2.76M
Avg Institutional Trade (90 D):	$2.02M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.72M
Avg Closing Trade (30 D):	$6.32M
Avg Closing Trade (90 D):	$2.91M
Avg Closing Volume:	89.67K

News

Jul 28, 2025 @ 12:25 PM Supernus Pharmaceuticals Announces Expiration of H... Source: Globe Newswire

Jul 5, 2025 @ 1:51 PM SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Invest... Source: Halper Sadeh Llc

Mar 14, 2025 @ 5:29 PM Notice to Long-Term Shareholders of Mercury System... Source: Grabar Law Office

Mar 13, 2025 @ 10:21 PM Long-Term Shareholder Notice: Fluence Energy, Inc.... Source: Grabar Law Office

Feb 25, 2025 @ 6:00 PM Comprehensive Market Analysis of Latest Published ... Source: Delveinsight

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS	$-4.89	$-.79	$-1.01
Diluted EPS	$-4.89	$-.79	$-1.01
Revenue	$70.41M	$31.66M	$14.06M
Gross Profit
Net Income / Loss	$-301.2M	$-49.65M	$-62.21M
Operating Income / Loss	$-324.82M	$-53.97M	$-67.46M
Cost of Revenue
Net Cash Flow	$-33.8M	$22.26M	$-35.8M
PE Ratio